Brain Metastases Clinical Trial
Official title:
A Randomised Controlled Trial Comparing the Accuracy and Acceptability of Closed-face and Open-face Thermoplastic Immobilisation Shells in Cranial Radiotherapy
Patients having radiotherapy to their head and neck wear an immobilisation shell to prevent
patient movement and improve treatment accuracy. These shells tend to cover the face and have
the potential to cause anxiety and distress in patients, particularly if they suffer with
claustrophobia or a similar fear. The study will use an 'open-face' shell that does not cover
the face and compare this with the investigators' current 'closed-face' shell. The
investigators will obtain treatment verification x-ray images to assess the daily set-up
errors and compare these between the two shell type, and ask both patients and radiographers
of their experiences from using the shells.
Hypothesis: Open-face immobilisation shells offer equivalent accuracy and efficiency of
radiotherapy delivery and are better accepted by patients and radiographers as compared to
closed-face immobilisation shells for cranial radiotherapy.
Patients will be randomised into one of two groups, with group A acting as the control group
using the investigators' standard 3--point closed--face shell, and group B using the 3--point
open--face shell (experimental group). Each procedure is discussed with the patient before
commencement. Patients will be positioned into the optimal treatment position and the shell
will be fabricated as per manufacturer instructions by pre-treatment radiographers. This is
followed by the patient having a planning CT scan of their head while wearing their shell to
allows radiographers and doctors to localise and plan the treatment. At the end of this
appointment, the patient will be asked to complete the first of three questionnaires
regarding their experience of wearing the shell. Radiographers will be asked to complete a
questionnaire of their experience of using the shell, and complete timing data for the
procedures.
On the first day of treatment, radiographers will discuss the treatment process and side
effects of treatment with the patient, and treatment will be delivered under current
department protocols using linear accelerators (linacs). During the course of the treatment,
radiographers will obtain 5 sets of verification images for the study, and these will be
assessed for set-up errors as per current department policy. Where possible, treatment fields
will be used to verify patient position to keep radiation doses from verification imaging as
low as reasonably practicable (ALARP). Patients will be asked to complete two more
questionnaires on their experience, one on their first day and one on their last day of
treatment. Radiographers will also complete questionnaires on these days. Timing data will be
obtained for all treatment fractions.
The patient's perspective of the planning and treatment processes will be almost identical to
that of patients having cranial radiotherapy that are not in the trial. The only differences
that will be observed will be the use of an open-face shell (for patients in group B),
completion of three questionnaires, and additional verification imaging.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04074096 -
Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis
|
Phase 2 | |
Recruiting |
NCT04474925 -
Pre- Versus Post-operative SRS for Resectable Brain Metastases
|
Phase 3 | |
Recruiting |
NCT05358340 -
Dual Perfusion Imaging for Characterizing Vascular Architecture of Brain Lesions
|
N/A | |
Recruiting |
NCT05559853 -
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
|
||
Completed |
NCT03189381 -
Pilot Phase 2 Study Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases
|
N/A | |
Completed |
NCT02082587 -
Toronto BNB Pilot Study
|
N/A | |
Terminated |
NCT01551680 -
A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases
|
Phase 1 | |
Terminated |
NCT00717275 -
Study of Temozolomide to Treat Newly Diagnosed Brain Metastases
|
Phase 2 | |
Recruiting |
NCT05048212 -
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
|
Phase 2 | |
Recruiting |
NCT03714243 -
Blood Brain Barrier Disruption (BBBD) Using MRgFUS in the Treatment of Her2-positive Breast Cancer Brain Metastases
|
N/A | |
Recruiting |
NCT05573815 -
Evaluation of Clinical Decision Support System for Brain Metastasis Using Brain MR Images
|
N/A | |
Recruiting |
NCT04899908 -
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
|
Phase 2 | |
Completed |
NCT04507217 -
Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC
|
Phase 2 | |
Recruiting |
NCT05452005 -
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT06457906 -
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
|
Phase 3 | |
Completed |
NCT04170777 -
Perfexion Registration Using CBCT
|
||
Recruiting |
NCT03027544 -
Tomotherapy for Refractory Brain Metastases
|
N/A | |
Completed |
NCT04178330 -
Tomotherapy as Primary Radiotherapy for Multipule Brain Metastases
|
N/A | |
Terminated |
NCT02187822 -
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
|
Phase 1 | |
Terminated |
NCT00538343 -
RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases
|
Phase 2 |